the late effects of anthracyclines among longterm survivors of childhood cancer J Am Coll Cardiol 2013;61(14):1539–1547 32 Tham EB, Haykowsky MJ, Chow K, et al Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance.2013;15:48 33 Nawaytou H, Bernstein HS Biomarkers in pediatric heart disease Biomark Med 2014;8(7):943–963 34 Lipshultz SE, Rifai N, Dalton VM, et al The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 2004;351(2):145–153 35 Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature Pediatr Hematol Oncol 2008;25(7):655–664 36 Lipshultz SE, Scully RE, Lipsitz SR, et al Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial Lancet Oncol 2010;11(10):950–961 37 Lipshultz SE, Miller TL, Scully RE, et al Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes J Clin Oncol 2012;30(10):1042– 1049 38 Lipshultz SE, Rifai N, Sallan SE, et al Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury Circulation 1997;96(8):2641–2648 39 Aggarwal S, Pettersen MD, Bhambhani K, et al B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children Pediatr Blood Cancer 2007;49(6):812–816 40 Mladosievicova B, Urbanova D, Radvanska E, Slavkovsky P, Simkova I Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines J Exp Clin Cancer Res 2012;31:86 41 Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, et al Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines Pediatr Blood Cancer 2009;52(5):631–636 42 Sherief LM, Kamal AG, Khalek EA, et al Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children Hematology 2012;17(3):151–156 43 Kim YH, Kirsop J, Tang WH Alternative biomarkers for combined biology Heart failure clinics.2017;13(2):381–401 44 Leger KJ, Leonard D, Nielson D, et al Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy J Am Heart Assoc 2017;6(4) 45 Visscher H, Ross CJ, Rassekh SR, et al Pharmacogenomic prediction of anthracyclineinduced cardiotoxicity in children J Clin Oncol 2012;30(13):1422–1428 46 Blanco JG, Sun CL, Landier W, et al Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the Children's oncology group J Clin Oncol 2012;30(13):1415–1421 ... Lipshultz SE, Miller TL, Scully RE, et al Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic... 2012;30(10):1042– 1049 38 Lipshultz SE, Rifai N, Sallan SE, et al Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury Circulation 1997;96(8):2641–2648 39 Aggarwal S, Pettersen MD, Bhambhani K, et al